Novel Oral RdRp Inhibitor SHEN26 Shows Promise in Phase II COVID-19 Trial

A new Phase II clinical trial has revealed promising results for SHEN26 (formerly ATV014), an oral RNA-dependent RNA polymerase (RdRp) inhibitor, in treating mild-to-moderate COVID-19 patients. The multicenter, randomized, double-blind, placebo-controlled study conducted in China demonstrates significant viral load reduction in early treatment stages.

The trial, conducted between December 2022 and January 2023, enrolled 79 patients across multiple research centers in China. Participants were randomized into three groups receiving either 400mg (high-dose), 200mg (low-dose), or placebo, administered twice daily for five days.

Significant Early Viral Load Reduction

The high-dose (400mg) group showed superior efficacy compared to both placebo and low-dose groups. On day 3, the 400mg group achieved a significant viral load reduction of 1.06 log10 copies/mL compared to placebo (P = 0.0119). By day 5, the difference increased to 1.21 log10 copies/mL (P = 0.0120), demonstrating the drug's potent antiviral activity during early treatment phases.

Safety Profile and Tolerability

SHEN26 demonstrated a favorable safety profile across both dosage groups. No severe adverse events (CTCAE ≥ 3) related to the drug were reported, and there were no treatment discontinuations due to adverse events. Importantly, the drug showed no negative impact on hepatic or renal function, addressing key safety concerns for antiviral medications.

Clinical Implications

The study builds on previous Phase I results that established SHEN26's safety in healthy volunteers. As an oral RdRp inhibitor, SHEN26 represents a new class of COVID-19 therapeutics, joining the limited arsenal of oral antiviral treatments available for early-stage disease management.

Dr. Sun, who led the earlier Phase I trial, noted that SHEN26's mechanism of action involves formation of GS-441,524, the active metabolite also produced by remdesivir, but with the advantage of oral administration.

Study Limitations and Future Directions

While the results are promising, the researchers acknowledge several limitations, including the relatively small sample size of 79 patients and the predominance of mild cases in the study population. Only three moderate cases were included, limiting conclusions about efficacy in more severe disease.

A larger Phase III trial is planned to further evaluate SHEN26's impact on symptom amelioration and clinical outcomes across a broader patient population. The current findings suggest that the 400mg dose may be optimal for future clinical development.